tradingkey.logo
tradingkey.logo
Search

Standard BioTools Inc

LAB
Add to Watchlist
0.770USD
+0.040+5.48%
Close 09-17 16:00ET
300.36MMarket Cap
3.83P/E TTM

More Details of Standard BioTools Inc Company

Standard BioTools Inc. develops, manufactures and sells a diversified range of instrumentation, consumables, and services that help scientists and biomedical researchers. The Company's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The Company works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. It offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.

Standard BioTools Inc Profile

Ticker SymbolLAB
Company nameStandard BioTools Inc
IPO dateFeb 10, 2011
CEOEgholm (Michael)
Number of employees818
Security typeOrdinary Share
Fiscal year-endFeb 10
Address2 Tower Place
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16502666000
Websitehttps://www.standardbio.com/
Ticker SymbolLAB
IPO dateFeb 10, 2011
CEOEgholm (Michael)

Company Executives of Standard BioTools Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Sean Mackay
Mr. Sean Mackay
Chief Business Officer
Chief Business Officer
732.08K
-3.51%
Mr. Sean Mackay
Mr. Sean Mackay
Chief Business Officer
Chief Business Officer
732.08K
-3.51%
Mr. Sean Mackay
Mr. Sean Mackay
Chief Business Officer
Chief Business Officer
732.08K
-3.51%
Mr. Fenel M. Eloi
Mr. Fenel M. Eloi
Independent Director
Independent Director
317.28K
+61.05%
Mr. Fenel M. Eloi
Mr. Fenel M. Eloi
Independent Director
Independent Director
317.28K
+61.05%
Mr. Fenel M. Eloi
Mr. Fenel M. Eloi
Independent Director
Independent Director
317.28K
+61.05%
Dr. Franklin R. (Frank) Witney, Ph.D.
Dr. Franklin R. (Frank) Witney, Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Egholm, Ph.D.
Dr. Michael Egholm, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Hanjoon Alex Kim
Mr. Hanjoon Alex Kim
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Eli D. Casdin
Mr. Eli D. Casdin
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Sean Mackay
Mr. Sean Mackay
Chief Business Officer
Chief Business Officer
732.08K
-3.51%
Mr. Sean Mackay
Mr. Sean Mackay
Chief Business Officer
Chief Business Officer
732.08K
-3.51%
Mr. Sean Mackay
Mr. Sean Mackay
Chief Business Officer
Chief Business Officer
732.08K
-3.51%
Mr. Fenel M. Eloi
Mr. Fenel M. Eloi
Independent Director
Independent Director
317.28K
+61.05%
Mr. Fenel M. Eloi
Mr. Fenel M. Eloi
Independent Director
Independent Director
317.28K
+61.05%
Mr. Fenel M. Eloi
Mr. Fenel M. Eloi
Independent Director
Independent Director
317.28K
+61.05%

FAQs

Who are the top five shareholders of Standard BioTools Inc?

The top five shareholders of Standard BioTools Inc are: Mr. Sean Mackay

How many institutions hold shares of Standard BioTools Inc (LAB)?

As of 2026Q1, 342 institutions hold shares of Standard BioTools Inc, with a combined market value of approximately 317.36M, accounting for 81.30% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 773508.00.

What is the biggest source of revenue for Standard BioTools Inc?

In 2026Q1, the Consumables business generated the highest revenue for Standard BioTools Inc, amounting to 9.38M and accounting for 46.68% of total revenue.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.